Cefoxitin

Summary

Cefoxitin (CHEMBL996) is an approved small-molecule antibacterial drug (ATC J01DC01); indicated across 3 conditions including bacterial infectious disease and lung disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DC01
• Indications: 3 conditions
• Clinical trials: 11
• Chemistry: 427.5 Da · C16H17N3O7S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL996
Name	Cefoxitin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	441199
ChEBI	CHEBI:209807
ATC	J01DC01
Molecular formula	C16H17N3O7S2
Molecular weight	427.5
InChIKey	WZOZEZRFJCJXNZ-ZBFHGGJFSA-N

SMILES: CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3

IUPAC name: (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7α position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to β-lactamase.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefoxitin, Cefoxitina, Cefoxitine, Cenomycin, J01DC01, Mefoxitin, cefoxitin, Cefoxotin, CEFOXITIN, SID144206560, CEFOXITINE, SID170465105

Parent form; salt/anhydrous children: CHEMBL1200530

Patent coverage: 8,258 distinct patent families (30,961 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Organic anion transporter 3, Peroxisome proliferator-activated receptor gamma, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR1I2	5.62	AC50	2400	nM	CHEMBL_ACT_25188664
NR1I2	5.19	AC50	6400	nM	CHEMBL_ACT_25224093

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
lung disorder	2	MONDO:0005275	EFO:0003818
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
Not specified	4
PHASE4	2
PHASE3	2
PHASE2/PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02474706	PHASE4	TERMINATED	Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli
NCT02703857	PHASE4	COMPLETED	Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique
NCT04310930	PHASE2/PHASE3	RECRUITING	Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
NCT03269994	PHASE3	COMPLETED	Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
NCT05755789	PHASE3	UNKNOWN	Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery
NCT07485010	PHASE2	NOT_YET_RECRUITING	Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
NCT06860802	PHASE1	RECRUITING	Precision Antibiotic Dosing for Appendectomy
NCT01820793	Not specified	TERMINATED	Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli
NCT02800785	Not specified	COMPLETED	The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial
NCT02839486	Not specified	COMPLETED	Vancomycin and Cefoxitin During Pediatric Cardiopulmonary Bypass
NCT02985086	Not specified	UNKNOWN	Immediate Versus Delayed Induction in Term-PROM Using or Not Antibiotic Prophylaxis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).